Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
INVO Fertility ( (IVF) ) has issued an announcement.
INVO Fertility, Inc., a Nasdaq-listed fertility services provider operating four U.S. clinics and marketing its INVOcell-enabled intravaginal culture technology, has implemented a 1-for-5 reverse stock split of its common shares. The move affects both issued and outstanding stock as well as authorized shares, while preserving the company’s focus on expanding assisted reproductive technology access.
The reverse split was authorized via a Nevada Certificate of Change filed on March 25, 2026, and became effective at 12:01 a.m. Eastern on March 27, 2026, with the shares beginning split-adjusted trading on Nasdaq that same day under the unchanged ticker IVF. As part of the corporate action, outstanding shares were consolidated to approximately 1.6 million, the authorized share count was reset to 50 million, fractional positions were rounded up or cashed out through brokers, and the stock received a new CUSIP number, altering the company’s capital structure without changing total par value.
The most recent analyst rating on (IVF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Neutral.
The score is primarily held back by weak financial performance (persistent losses, declining gross margin, and negative operating/free cash flow). Technicals are only mildly supportive, while valuation lacks support due to negative earnings and no dividend data. Corporate events are mixed—growth initiatives and financing help, but dilution risk and the reverse split temper the upside.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility, Inc. is a healthcare services company focused on the fertility market, primarily building, acquiring and operating fertility clinics in the U.S., including dedicated INVO Centers and profitable IVF clinics. The company also sells and distributes its proprietary INVOcell device, which enables intravaginal culture procedures designed to offer a more natural and lower-cost alternative to traditional IVF and a more effective option than intrauterine insemination.
Average Trading Volume: 1,461,979
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.67M
For an in-depth examination of IVF stock, go to TipRanks’ Overview page.